Viyash Scientific signs SPA to acquire BioForLife Italia for about EUR 17 million

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.4%Reaction day

₹265.35

prior close

₹266.00

announcement price

After-mkt

timing

Nifty Microcap 250market-1.2%-2.2% vs market

Pharmaceuticals peers, median of 165sector-1.6%-1.8% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-2.3

15m

-3.0

30m

-3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.4-1.2-2.2-1.6-1.8

Next day

-4.7-1.9-2.9-2.4-2.3

-5.4-1.4-4.0-2.4-3.0

-1.9-0.1-1.7-1.3-0.6

-4.6-1.4-3.2-2.4-2.2

-3.4-1.0-2.4-1.7-1.6

-4.9-0.4-4.5-1.9-3.0

15d

-1.0+3.2-4.2-0.3-0.7

+2.9+4.4-1.5-1.1+4.0

-4.8+4.6-9.4+1.1-5.9

-21.5-3.6-17.9-6.4-15.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Viyash Scientific's step-down wholly owned subsidiary Alivira Animal Health has signed a Sale and Purchase Agreement to acquire 100% of Italy-based BioForLife Italia S.r.l. Base consideration is about EUR 16.976 million, with EUR 15 million payable at closing and about EUR 1.976 million as retained or deferred payment linked to contractual-continuation conditions. Closing is subject to Italian FDI or Golden Power clearance. Other terms remain unchanged from the June 8, 2026 disclosure.

Likely market impact

European expansion via acquisition; EUR 17 million deal pending Italian regulatory clearance.